Board of Directors
David Hochman, Chairman
Managing Partner, Orchestra Medical Ventures
David Hochman is a managing partner of Orchestra Medical Ventures, an investment firm that employs an innovative strategy to create, build and invest in medical technology companies intended to generate substantial clinical value and superior investor returns. He is also president of Accelerated Technologies, Inc. (ATI), a medical device accelerator managed by Orchestra.
With more than 18 years of venture capital and investment banking experience, Mr. Hochman is chairman of Vital Access Corp. and MOTUS GI Medical Technologies. He also serves as a director of Caliber Therapeutics, BackBeat Medical (where he is also president), FreeHold Surgical, Maternity Neighborhood, Corbus Pharmaceuticals and Naked Brand Group.
Mr. Hochman currently serves as a board member of two non-profit organizations: the Citizens Committee for New York City and the Mollie Parnis Livingston Foundation.
He graduated with honors from the University of Michigan.
Mark Pomeranz, Director
CEO, MOTUS GI
With 30 years of experience in the medical device industry, Mark Pomeranz brings a strong track record of success in both start-ups and in large multinational organizations.
Prior to joining MOTUS in 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems. Other previous positions include serving as a vice president at Johnson & Johnson and in senior leadership roles at Cardiac Pathways Corporations and Cardiovascular Imaging Systems, both acquired by Boston Scientific Corporation.
Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami and currently holds 40+ patents.
Darren R. Sherman, Director
Managing Partner, Orchestra Medical Ventures
Mr. Sherman is a managing partner of Orchestra Medical Ventures, an investment firm that employs an innovative strategy to create, build and invest in medical technology companies intended to generate substantial clinical value and superior investor returns. He is also Chief Technical Officer of Accelerated Technologies, Inc. (ATI) and CEO and director of Caliber Therapeutics, Inc., and FreeHold Surgical, Inc.
In addition to serving as a director of MOTUS GI Medical Technologies, Mr. Sherman holds that same role with Vital Access Corp., and BackBeat Medical.
He earned his Bachelor of Science degree in bioengineering from the University of California, San Diego and has authored 60+ U.S. patents with an additional 75+ published applications.
Gary Jacobs, Director
Managing Director, Jacobs Investing Company
In addition to being the managing director of Jacobs Investment Company, LLC, Mr. Jacobs serves on the boards of Next Generation Technologies and Fallbrook Technologies and is also chairman of Nutrina, Ltd., a biotechnology company focused on bioactive supplements for infant formulas.
Mr. Jacobs is actively involved with education and philanthropy, serving as Chairman of the Board of Trustees of High Tech High in San Diego and chair of the Dean’s Advisory Council for Social Sciences at the University of California, San Diego.
He received his Bachelor of Arts degree in management science from the University of California, San Diego.
Samuel R. Nussbaum, M.D., Director
Strategic Consultant with EBG Advisors, Inc.
Dr. Samuel Nussbaum brings expertise across the spectrum of health care. Having served as the Chief Medical Officer of WellPoint/Anthem and, previously, Executive Vice President for BJC HealthCare, he has executive experience in population health, care management, data analytics, provider contracting, and medical and pharmacy policy and contracting. As a professor and clinical leader at Harvard Medical School and Massachusetts General Hospital he has led basic science research, drug discovery, clinical studies, teaching and patient care.
Dr. Nussbaum serves as Chair of a public-private work group established by the Department of Health and Human Services to develop the framework for alternate payment models to enhance patient-centered care and reduce waste in healthcare. Dr. Nussbaum brings deep knowledge of the drivers of health care costs, including specialty pharmaceuticals, and has crafted strategies and applied solutions to better manage these costs for Medicare, Medicaid, and commercial health plans. He has led public health initiatives to improve diabetes care, childhood obesity and hospital safety and quality.
Dr. Nussbaum received his undergraduate degree from New York University and his MD from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology and metabolism at Harvard Medical School and Massachusetts General Hospital. Dr. Nussbaum is a Professor of Clinical Medicine at Washington University School of Medicine and serves as adjunct professor at the Olin School of Business, Washington University.
Chief Financial Officer and Chief Strategy Officer of Beaver-Visitec International
Mr. Korangy is a seasoned executive with broad expertise, having more than 20 years of experience in investing and operating roles across a wide range of industries. He currently serves as the Chief Financial Officer and Chief Strategy Officer of Beaver-Visitec International (“BVI”), a leading global developer, manufacturer and marketer of surgical devices for the ophthalmic marketplace. Prior to his appointment at BVI, Mr. Korangy was a senior executive at Novartis Group AG (NYSE: NVS), where he served as the Global Head of Corporate Finance as well as several general management assignments in multiple countries. Prior to joining Novartis in 2010, Mr. Korangy served as a Managing Director at The Blackstone Group (NYSE: BX), where he spent approximately 15 years splitting time in the firm’s restructuring and private equity businesses. He currently serves on the Board of Directors of Pelican Rouge BV and has previously served on several corporate boards.